Get the Stockscreener App
27.81
4.47%
1.19
After Hours:
27.81
Oruka Therapeutics Inc stock is traded at $27.81, with a volume of 453.81K.
It is up +4.47% in the last 24 hours and down -9.82% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$26.62
Open:
$27.27
24h Volume:
453.81K
Relative Volume:
0.87
Market Cap:
$1.35B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.25%
1M Performance:
-9.82%
6M Performance:
+109.26%
1Y Performance:
+46.45%
1-Day Range:
$26.78
$28.51
1-Week Range:
$25.23
$30.61
52-Week Range:
$5.485
$32.64
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
27.81 | 1.29B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3%What's Next? - MarketBeat
Oruka Therapeutics Builds Oncology Programs at Molecular Level - Kalkine Media
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka T - GuruFocus
Oruka Therapeutics COO Sandler sells $370,795 in shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $370,795 in shares - Investing.com UK
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD By Investing.com - Investing.com Australia
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyMarket Sentiment Report & Fast Exit Strategy with Risk Control - Улправда
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3%Here's What Happened - MarketBeat
Why Oruka Therapeutics Inc. stock is a must watch in 2025Recession Risk & Real-Time Chart Pattern Alerts - DonanımHaber
Piper Sandler Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. stock compares to growth peersWeekly Gains Report & AI Based Buy and Sell Signals - Улправда
Is Oruka Therapeutics Inc. stock a dividend growth opportunityJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - Улправда
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors - TipRanks
Oruka Therapeutics Earnings Notes - Trefis
Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors By Investing.com - Investing.com India
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors - Investing.com
Oruka Therapeutics Appoints Christopher Martin to Board - TipRanks
Oruka Therapeutics Announces New Board Member and Board Transition - The Manila Times
B Group Inc. Increases Position in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics (ORKA) Stock Analysis Report | Financials & Insights - Benzinga
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Geode Capital Management LLC - Defense World
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Affinity Asset Advisors LLC - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com Nigeria
Can Oruka Therapeutics Inc. stock deliver consistent earnings growthCEO Change & AI Based Buy and Sell Signals - Newser
Will Oruka Therapeutics Inc. stock sustain high P E ratios2025 Volatility Report & Safe Capital Growth Plans - Newser
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliable2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics stock hits 52-week high, reaching $31.01 - Investing.com
Should I hold or sell Oruka Therapeutics Inc. stock in 2025Market Movement Recap & AI Based Buy and Sell Signals - Newser
Is Oruka Therapeutics Inc. (HQ1) stock undervalued at current priceJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Will Oruka Therapeutics Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Sale |
28.52 |
13,000 |
370,795 |
205,084 |
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):